Janssen Announces Phase 2b Data Demonstrating its Investigational RSV Adult Vaccine Provided 80% Protection Against Lower Respiratory Infections in Older Adults
- EMEA Innovative Medicine
- Janssen Announces Phase 2b Data Demonstrating its Investigational RSV Adult Vaccine Provided 80% Protection Against Lower Respiratory Infections in Older Adults
Janssen Announces Phase 2b Data Demonstrating its Investigational RSV Adult Vaccine Provided 80% Protection Against Lower Respiratory Infections in Older Adults
- X (Twitter)
Copy link